About
Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, oncology, and dermatology in various dosage forms, including injectables, solid orals, liquid orals, and topicals. The company was founded in 1988 and is based in Hyderabad, India.
Key Metrics
as of Sep 2026Market Cap2,296 Cr
P/E111.00
Div Yield0.00 %
Book Value—
52w High₹706.00
52w Low₹400.00
Face Value₹5.00
Quarterly Results
Rs. Crores · hover row for definition| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Sales | 52.78 | 56.79 | 38.48 | 19.20 |
| Expenses | 39.43 | 43.56 | 34.51 | 16.17 |
| Operating Profit | 13.35 | 13.23 | 3.97 | 3.03 |
| OPM % | 25.29 | 23.30 | 10.32 | 15.78 |
| Other Income | 3.41 | 0.12 | 0.75 | 1.24 |
| Depreciation | 1.36 | 1.53 | 1.60 | 1.32 |
| Interest | 3.57 | 3.42 | 2.12 | 1.76 |
| Profit before tax | 11.83 | 8.40 | 1.00 | 1.19 |
| Tax % | 24.94 | -18.45 | 64.00 | 30.25 |
| Net Profit | 8.88 | 9.95 | 0.36 | 0.83 |
| EPS in Rs | 2.01 | 2.25 | 0.10 | 0.30 |
Profit & Loss
Annual · Rs. Crores| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Sales | 166.00 | 127.00 | 114.00 | 97.00 |
| Expenses | 137.00 | 100.00 | 92.00 | 79.00 |
| Operating Profit | 28.00 | 27.00 | 21.00 | 18.00 |
| OPM % | 17.00 | 21.00 | 19.00 | 18.00 |
| Other Income | 5.00 | 0.00 | 1.00 | 0.00 |
| Interest | 9.00 | 7.00 | 6.00 | 5.00 |
| Depreciation | 6.00 | 5.00 | 6.00 | 6.00 |
| Profit before tax | 19.00 | 14.00 | 10.00 | 7.00 |
| Tax % | 11.00 | 28.00 | 30.00 | 37.00 |
| Net Profit | 17.00 | 10.00 | 7.00 | 5.00 |
| EPS in Rs | 3.80 | 3.86 | 5.40 | 6.43 |
| Dividend Payout % | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Equity Capital | 22.00 | 13.00 | 13.00 | 7.00 |
| Reserves | 465.00 | 78.00 | 65.00 | 24.00 |
| Borrowings | 133.00 | 72.00 | 71.00 | 69.00 |
| Other Liabilities | 184.00 | 52.00 | 45.00 | 34.00 |
| Total Liabilities | 804.00 | 215.00 | 194.00 | 134.00 |
| Fixed Assets | 43.00 | 40.00 | 41.00 | 44.00 |
| CWIP | 1.00 | 0.00 | 0.00 | 2.00 |
| Investments | 158.00 | 28.00 | 28.00 | 0.00 |
| Other Assets | 602.00 | 146.00 | 124.00 | 88.00 |
| Total Assets | 804.00 | 215.00 | 194.00 | 134.00 |
Cash Flows
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Cash from Operating Activity | 112.00 | 19.00 | -4.00 | -21.00 |
| Cash from Investing Activity | -136.00 | -13.00 | -32.00 | -17.00 |
| Cash from Financing Activity | 433.00 | -6.00 | 36.00 | 30.00 |
| Net Cash Flow | 409.00 | 0.00 | -1.00 | -8.00 |
| Free Cash Flow | 105.00 | 14.00 | -7.00 | -38.00 |
| CFO/OP % | 413.00 | 77.00 | -6.00 | -103.00 |
Ratios
Annual · Days / % — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Debtor Days | 179.00 | 249.00 | 272.00 | 231.00 |
| Inventory Days | 208.00 | 130.00 | 97.00 | 83.00 |
| Days Payable | 89.00 | 160.00 | 156.00 | 140.00 |
| Cash Conversion Cycle | 298.00 | 219.00 | 213.00 | 174.00 |
| Working Capital Days | -212.00 | 52.00 | 70.00 | 27.00 |
| ROCE % | 7.00 | 14.00 | 13.00 | — |
Corporate Actions
No corporate actions recorded.